US
US Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $1.27 Bn.
Canada at 10.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.27 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.18 Bn | — | — |
| 2025 (base) | $1.27 Bn | +$94.3 Mn | — |
| 2026 (forecast) | $1.38 Bn | +$101.9 Mn | +8% |
| 2027 (forecast) | $1.49 Bn | +$110.0 Mn | +16.6% |
| 2028 (forecast) | $1.60 Bn | +$118.9 Mn | +26% |
| 2029 (forecast) | $1.73 Bn | +$128.4 Mn | +36% |
| 2030 (forecast) | $1.87 Bn | +$138.6 Mn | +46.9% |
| 2031 (forecast) | $2.02 Bn | +$149.7 Mn | +58.7% |
| 2032 (forecast) | $2.18 Bn | +$161.7 Mn | +71.4% |
| 2033 (forecast) | $2.36 Bn | +$174.6 Mn | +85.1% |
| 2034 (forecast) | $2.55 Bn | +$188.6 Mn | +99.9% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$1.27 Bn
Canada
$238.1 Mn
Japan
$225.2 Mn
China
$224.6 Mn
Germany
$98.1 Mn
France
$92.2 Mn
Brazil
$87.5 Mn
UK
$82.5 Mn
Italy
$72.6 Mn
India
$67.4 Mn
Saudi Arabia
$61.2 Mn
Ecuador
$59.7 Mn
Spain
$52.6 Mn
Mexico
$52.1 Mn
Australia
$36.2 Mn
New Zealand
$33.0 Mn
Russia
$31.8 Mn
South Africa
$20.7 Mn
UAE
$15.7 Mn
Egypt
$8.8 Mn
Philippines
$7.7 Mn
Malaysia
$5.7 Mn
Hong Kong
$5.1 Mn
Thailand
$3.8 Mn
Singapore
$3.7 Mn
Kenya
$2.2 Mn
Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.
Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.
The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
Pharmaceuticals · US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Digital Health · US
Healthcare Services · US